Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 3/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 6/20 | 0.42 |
| ▸ | HTR2B | P41595 | 5/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27587863 | 0.92 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL9382691 | 0.85 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL21359788 | 0.85 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL11958335 | 0.85 | HTR3A (0.49) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL1945287 | 0.83 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL9678865 | 0.81 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL164537 | 0.81 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL13699524 | 0.81 | SLC6A2 (0.59) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL1948114 | 0.80 | SLC6A2 (0.44) | SLC6A2SLC6A4SLC6A3CYP2D6HTR2C | |
| SCHEMBL5632812 | 0.79 | RAD52 (0.46) | SLC6A2SLC6A4SLC6A3HTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY (JP) | 2016-03-03 | — | — | US | disclosed |
| CN-105188692-A | Therapeutic agent for type 2 diabetes | UNIV KUMAMOTO NAT UNIV CORP | 2015-12-23 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160060235-A1 | Therapeutic Agent for Type 2 Diabetes | RNASE1, CDKL2, CDKL1 | SLC6A2 4046/4885SLC6A4 4717/4885SLC6A3 3762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.